复方苦参注射液联合甲磺酸奥希替尼片治疗表皮生长因子受体基因突变型晚期非小细胞肺癌临床研究  

Clinical Study on Compound Kushen Injection Combined with Osimertinib Mesylate Tablets for Epidermal Growth Factor Receptor Gene Mutation in Advanced NonSmall Cell Lung Cancer

作　　者：应卫平 钟国美 YING Weiping;ZHONG Guomei(Department of Respiratory Medicine,Zhejiang jinhua Guangfu Tumor Hospital,Jinhua Zhejiang 321000,China)

机构地区：[1]浙江金华广福肿瘤医院呼吸内科,浙江金华321000

出　　处：《新中医》2024年第2期147-150,共4页New Chinese Medicine

摘　　要：目的:观察复方苦参注射液联合甲磺酸奥希替尼片治疗痰湿毒蕴型表皮生长因子受体(EGFR)基因突变型晚期非小细胞肺癌(NSCLC)的临床疗效。方法:回顾性分析80例痰湿毒蕴型EGFR基因突变型晚期NSCLC患者的临床资料,根据治疗方法不同分成观察组和对照组各40例,观察组采用复方苦参注射液联合甲磺酸奥希替尼片治疗,对照组单纯采用甲磺酸奥希替尼片治疗。2组均以治疗6周为1个疗程,共治疗2个疗程。治疗前后评价Karnofsky功能状态评分(KPS评分),比较2组的临床疗效、不良反应发生率。结果:治疗后,观察组疾病控制率高于对照组(P<0.05);2组客观缓解率、不良反应发生率比较,差异均无统计学意义(P>0.05)。观察组KPS评分高于治疗前(P<0.05);对照组KPS评分高于治疗前,但差异无统计学意义(P>0.05)。观察组KPS评分高于对照组(P<0.05)。结论:采用复方苦参注射液联合甲磺酸奥希替尼片治疗痰湿毒蕴型EGFR基因突变型晚期NSCLC的患者,能够提高疗效,减少不良反应的发生,对患者的健康状况有明显的改善作用。Objective:To observe the clinical effect of Compound Kushen Injection combined with Osimertinib Mesylate Tablets for epidermal growth factor receptor(EGFR) gene mutation in advanced nonsmall cell lung cancer(NSCLC) with phlegm-damp toxin accumulation syndrome.Methods:The clinical data of 80 patients with EGFR gene mutation in advanced NSCLC of phlegm-damp toxin accumulation type were given retrospective analysis.According to different treatment methods,the patients were divided into the observation group and the control group,with 40 cases in each group.The observation group was treated with Compound Kushen Injection combined with Osimertinib Mesylate Tablets,and the control group was simply treated with Osimertinib Mesylate Tablets.Both groups were treated for two courses,with 6 weeks being one course.The Karnofsky Performance Scale(KPS) scores were evaluated before and after treatment.The clinical effects and incidence of adverse reactions were compared between the two groups.Results:After treatment,the disease control rate in the observation group was higher than that in the control group(P<0.05);there was no significant difference in the objective remission rates and incidences of adverse reactions between the two groups(P>0.05).The KPS score in the observation group was higher than that before treatment(P<0.05);the KPS score in the control group was higher than that before treatment,but the difference was not significant(P>0.05).The KPS score in the observation group was higher than that in the control group(P<0.05).Conclusion:The application of Compound Kushen Injection combined with Osimertinib Mesylate Tablets in the treatment of advanced NSCLC patients with EGFR gene mutation of phlegm-damp toxin accumulation type can improve the curative effects,reduce the incidence of adverse reactions,and have a significant improvement effect on the patient's health status.

关 键 词：非小细胞肺癌 表皮生长因子受体基因突变 痰湿毒蕴证 复方苦参注射液 Karnofsky功能状态评分 

分 类 号：R734.2[医药卫生—肿瘤]